In the SELECT trial, semaglutide reduced the incidence of major adverse cardiovascular events, including heart attack and stroke, by 20% in individuals with established cardiovascular disease and obesity but without diabetes [10]
Evidently, most patients lose an average of 15% of their body weight after 1 year
Even if you meet the BMI criteria, certain medical conditions may prevent you from taking specific weight loss medications
The compounded version allows for more granular dose adjustments, which is one of the arguments compounding pharmacies make for their products
Triple receptor agonist: GLP-1 + GIP + Glucagon Latest Phase 3 Highlights (23 July 2026) TRIUMPH-2 22.6% mean weight loss in adults with obesity and cardiovascular disease TRIUMPH-3 20.8% mean weight loss in adults with obesity and type 2 diabetes ~1.6% HbA1c reduction Next milestone Eli Lilly plans to submit its first FDA application for Retatrutide in Q1 2027
How To Use: If your concern is how to get clear skin naturally, walnuts are a great solution